Hydrix Limited (HYD) AI Stock Analysis

• Market Cap: AU$4.09M
• Dividend Yield: N/A
• Average Volume (3M): 49.41K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.05
• Revenue Growth: -13.05%
• EPS Growth: -184.09%
• Country: AU
• Employees: 55
• Sector: Technology
• Sector Strength: 82
• Industry: Hardware, Equipment & Parts
• EPS (TTM): -0.03
• Shares Outstanding: 272,768,860
• 10 Day Avg. Volume: 33,058
• 30 Day Avg. Volume: 49,411
• PEG Ratio: -0.02
• Price to Book (P/B): -1.08
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.12
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Hydrix Limited is currently facing significant financial headwinds due to declining revenues and high leverage. The stock's technical indicators are stable but lack positive momentum. The valuation metrics indicate financial distress, with a negative P/E ratio and no dividend yield. These factors collectively contribute to the low overall score.

Hydrix Limited Business Overview & Revenue Model

Company Description

Hydrix Limited (HYD) is an Australian-based company specializing in the design, development, and commercialization of high-technology solutions across various sectors. The company focuses on medical technology, safety-critical systems, and product innovation. Hydrix Limited offers a range of services including product development, engineering design, and regulatory compliance, catering primarily to the medical device and safety technology industries.

How the Company Makes Money

Hydrix Limited generates revenue through a diversified model primarily focused on service fees and product sales. The company earns income by providing engineering and design services for the development of complex products, particularly in the medical technology sector. Additionally, Hydrix engages in licensing arrangements and partnerships that allow it to commercialize innovative technologies. Another significant revenue stream comes from the sale of proprietary products and solutions, developed either in-house or through collaborations. The company's financial performance is further bolstered by strategic partnerships with leading firms in the medical and safety technology fields, enhancing its ability to deliver comprehensive solutions and expand its market reach.

Hydrix Limited Financial Statement Overview

Summary

Hydrix Limited faces substantial financial challenges across key areas, with declining revenues, negative profit margins, high leverage, and cash flow deficiencies. The company needs to address operational inefficiencies and improve its capital structure to stabilize its financial health.

Income Statement

Hydrix Limited's income statement indicates financial challenges, with declining revenue and negative profit margins. The company reported a significant net loss, and both EBIT and EBITDA margins are negative, reflecting operational inefficiencies. The revenue growth rate is negative, showing a downward trend in sales.

Balance Sheet

The balance sheet reveals a precarious financial position, with negative stockholders' equity indicating potential solvency issues. The high debt-to-equity ratio highlights significant leverage, increasing financial risk. The equity ratio is also negative, suggesting that liabilities exceed assets.

Cash Flow

Cash flow analysis shows persistent negative free cash flow, indicating the company is not generating sufficient cash to cover its capital expenditures. The operating cash flow to net income ratio is unfavorable, reflecting cash flow challenges. However, some relief is provided by positive financing cash flow.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
10.32M	10.61M	13.16M	10.33M	7.45M	14.93M
	Gross Profit
9.68M	9.79M	-638.73K	-3.31M	-6.46M	569.70K
	EBIT
-400.27K	-4.75M	-4.00M	-5.98M	-8.93M	-2.40M
	EBITDA
-2.50M	-7.92M	1.30M	-4.05M	-6.34M	-1.23M
	Net Income Common Stockholders
-6.40M	-9.56M	-396.93K	-5.55M	-9.78M	-3.22M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
847.28K	914.27K	1.15M	1.94M	6.65M	1.69M
	Total Assets
11.70M	8.62M	14.58M	15.94M	19.38M	20.50M
	Total Debt
5.94M	7.61M	4.73M	5.40M	5.97M	9.92M
	Net Debt
5.10M	6.69M	3.58M	3.46M	-673.27K	8.23M
	Total Liabilities
9.07M	11.98M	8.22M	12.66M	13.67M	18.20M
	Stockholders Equity
2.64M	-3.36M	6.35M	3.28M	5.71M	2.30M
Cash Flow		Free Cash Flow
-367.89K	-1.91M	-3.32M	-6.75M	-3.35M	-1.37M
	Operating Cash Flow
-359.81K	-1.89M	-3.12M	-6.58M	-2.86M	-1.32M
	Investing Cash Flow
157.07K	-53.43K	-209.71K	-306.65K	-641.56K	-1.07M
	Financing Cash Flow
471.87K	1.71M	2.54M	2.18M	8.46M	3.84M

Hydrix Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HYD, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and above the 200-day MA of 0.01, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 65.00 is Neutral, neither overbought nor oversold. The STOCH value of 194.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:HYD.

Hydrix Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RHT	64 Neutral	AU$17.47M	140.00	-3.11%	―	89.13%	69.57%
Sector *	60 Neutral	$11.64B	10.63	-6.94%	2.93%	7.63%	-11.15%
PYC	50 Neutral	AU$734.91M	―	-112.97%	―	―	-84.82%
HYD	44 Neutral	AU$4.09M	―	-637.73%	―	-13.05%	-184.09%
BRN	40 Underperform	$460.93M	―	-133.28%	―	72.47%	20.08%
4DX	39 Underperform	AU$132.91M	―	-52.37%	―	471.29%	-4.58%
BIT	36 Underperform	$3.98M	―	-119.28%	―	―	64.10%

Hydrix Limited Corporate Events

Hydrix Limited Announces Cessation of Securities

Hydrix Limited announced the cessation of 11,250 securities due to the lapse of conditional rights, as the conditions for these securities were not met by the deadline of March 31, 2025. This announcement may impact the company’s capital structure and could have implications for its stakeholders, reflecting on the company’s strategic adjustments in managing its securities.

Hydrix Limited Announces Cessation of Securities

Hydrix Limited announced the cessation of 10,000 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could have implications for stakeholders regarding the company’s financial strategies and market positioning.

Hydrix Limited Announces Cessation of Securities

Hydrix Limited announced the cessation of certain securities due to the lapse of conditional rights, as the conditions were not met. This cessation involves 3,150 options that were set to expire in June 2027, impacting the company’s issued capital and potentially affecting investor perceptions of its financial strategies.

Hydrix Limited Reports Strong Financial Performance and Growth Prospects

Hydrix Limited reported consecutive profitable quarters for its services division, driven by improved margins, increased billable utilization, and reduced operating costs. The company achieved a 37% increase in contract sales orders, with significant contributions from international clients and cardiac monitoring products. The recent FDA clearance for Gyder Surgical’s Hip Navigation System underscores Hydrix’s expertise in medical device development and boosts its venture investments. The company anticipates continued sales momentum and revenue growth, supported by a robust sales pipeline and strategic international market engagements.

Hydrix Limited Reports Improved Financial Performance Amid Revenue Decline

Hydrix Limited reported a decrease in revenue by 5.2% to $5,595,872 for the half-year ending December 2024, with a significant reduction in losses to $635,660 compared to the previous year’s $2,495,571. Despite the improved financial performance, the company does not plan to pay dividends, reflecting a strategic focus on reinvesting in its operations and future growth, which may impact stakeholders’ expectations regarding immediate returns.